New hope for protecting transplanted kidneys in diabetic patients
NCT ID NCT04918407
Summary
This study looked at whether adding the diabetes drug empagliflozin to insulin therapy could help reduce cell damage (oxidative stress) in people with type 2 diabetes who have received a kidney transplant. Forty patients were randomly assigned to receive either insulin alone or insulin plus empagliflozin for 90 days. Researchers measured specific markers in the blood to see if the added drug provided extra protection for the transplanted kidney.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT; COMPLICATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Labbafinezhd Hospital
Tehran, 166663423, Iran
-
SBMU
Tehran, 1666664321, Iran
Conditions
Explore the condition pages connected to this study.